Literature DB >> 26206574

Reversibility of liver fibrosis.

Mengxi Sun1, Tatiana Kisseleva2.   

Abstract

Liver fibrosis is a serious health problem worldwide, which can be induced by a wide spectrum of chronic liver injuries. However, until today, there is no effective therapy available for liver fibrosis except the removal of underlying etiology or liver transplantation. Recent studies indicate that liver fibrosis is reversible when the causative agent(s) is removed. Understanding of mechanisms of liver fibrosis regression will lead to the identification of new therapeutic targets for liver fibrosis. This review summarizes recent research progress on mechanisms of reversibility of liver fibrosis. While most of the research has been focused on HSCs/myofibroblasts and inflammatory pathways, the crosstalk between different organs, various cell types and multiple signaling pathways should not be overlooked. Future studies that lead to fully understanding of the crosstalk between different cell types and the molecular mechanism underlying the reversibility of liver fibrosis will definitely give rise to new therapeutic strategies to treat liver fibrosis.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26206574      PMCID: PMC4636085          DOI: 10.1016/j.clinre.2015.06.015

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  24 in total

1.  Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis.

Authors:  Johannes Kluwe; Nuttaporn Wongsiriroj; Juliane S Troeger; Geum-Youn Gwak; Dianne H Dapito; Jean-Philippe Pradere; Hongfeng Jiang; Maham Siddiqi; Roseann Piantedosi; Sheila M O'Byrne; William S Blaner; Robert F Schwabe
Journal:  Gut       Date:  2011-01-27       Impact factor: 23.059

2.  Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair.

Authors:  Jeremy S Duffield; Stuart J Forbes; Christothea M Constandinou; Spike Clay; Marina Partolina; Srilatha Vuthoori; Shengji Wu; Richard Lang; John P Iredale
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

3.  Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.

Authors:  Xiao Liu; Jun Xu; David A Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2013-09

Review 4.  Pathogenesis of liver fibrosis.

Authors:  R Alcolado; M J Arthur; J P Iredale
Journal:  Clin Sci (Lond)       Date:  1997-02       Impact factor: 6.124

Review 5.  Hepatic stellate cells and the reversal of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

6.  Adipogenic transcriptional regulation of hepatic stellate cells.

Authors:  Hongyun She; Shigang Xiong; Saswati Hazra; Hidekazu Tsukamoto
Journal:  J Biol Chem       Date:  2004-11-09       Impact factor: 5.157

Review 7.  History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells.

Authors:  A Geerts
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

8.  A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice.

Authors:  Juan E Puche; Youngmin A Lee; Jingjing Jiao; Costica Aloman; Maria I Fiel; Ursula Muñoz; Thomas Kraus; Tingfang Lee; Hal F Yee; Scott L Friedman
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

9.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

10.  Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.

Authors:  Tatiana Kisseleva; Min Cong; Yonghan Paik; David Scholten; Chunyan Jiang; Chris Benner; Keiko Iwaisako; Thomas Moore-Morris; Brian Scott; Hidekazu Tsukamoto; Sylvia M Evans; Wolfgang Dillmann; Christopher K Glass; David A Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

View more
  71 in total

1.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

2.  Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells.

Authors:  Zhongming Tan; Qianghui Liu; Runqiu Jiang; Long Lv; Siamak S Shoto; Isabelle Maillet; Valerie Quesniaux; Junwei Tang; Wenjie Zhang; Beicheng Sun; Bernhard Ryffel
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

3.  Silibinin Inhibits Proliferation and Migration of Human Hepatic Stellate LX-2 Cells.

Authors:  Devaraj Ezhilarasan; Jonathan Evraerts; Sid Brice; Pedro Buc-Calderon; Sivanesan Karthikeyan; Etienne Sokal; Mustapha Najimi
Journal:  J Clin Exp Hepatol       Date:  2016-01-13

Review 4.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

Review 5.  Transcriptional control of cardiac fibroblast plasticity.

Authors:  Janet K Lighthouse; Eric M Small
Journal:  J Mol Cell Cardiol       Date:  2015-12-22       Impact factor: 5.000

Review 6.  Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.

Authors:  Humberto C Gonzalez; Andrés Duarte-Rojo
Journal:  Curr Gastroenterol Rep       Date:  2016-07

7.  Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.

Authors:  Sandeep Nadella; Victor Ciofoaia; Hong Cao; Bhaskar Kallakury; Robin D Tucker; Jill P Smith
Journal:  Dig Dis Sci       Date:  2019-10-09       Impact factor: 3.199

8.  Diagnostic performance of quantitative magnetic resonance imaging biomarkers for predicting portal hypertension in children and young adults with autoimmune liver disease.

Authors:  Jonathan R Dillman; Suraj D Serai; Andrew T Trout; Ruchi Singh; Jean A Tkach; Amy E Taylor; Burns C Blaxall; Lin Fei; Alexander G Miethke
Journal:  Pediatr Radiol       Date:  2019-01-03

Review 9.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

10.  Costunolide represses hepatic fibrosis through WW domain-containing protein 2-mediated Notch3 degradation.

Authors:  Mao-Xu Ge; Hong-Tao Liu; Na Zhang; Wei-Xiao Niu; Zhen-Ning Lu; Yun-Yang Bao; Rui Huang; Dong-Ke Yu; Rong-Guang Shao; Hong-Wei He
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.